Association between
            <i>SLCO1B1</i>
            rs4149056 and Tegafur–Uracil-Induced Hepatic Dysfunction in Breast Cancer

Kamio, Hidenori; Uchiyama, Toshitaka; Kanno, Hitoshi; Onoe, Yoshiko; Saito, Kayoko; Kameoka, Shingo; Kamio, Takihiro; Okamoto, Takahiro

doi:10.2217/pgs-2018-0100

Cited by 2 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A meta-analysis revealed an association between the SLCO1B1 521T>C polymorphism and the risk of statin-induced adverse drug reactions including an abnormal alanine transaminase (ALT) level [23]. Another study including patients with breast cancer receiving tegafur–uracil also showed that patients with the CC or CT genotypes had higher risk of aspartate aminotransferase and ALT level elevation compared to those with the TT genotype [24]. These studies confirmed an association between the SLCO1B1 521T>C polymorphism and drug-induced hepatotoxicity.…”

Section: Discussionmentioning

confidence: 99%

Association between SLCO1B1 polymorphism and methotrexate-induced hepatotoxicity: a systematic review and meta-analysis

Han

Choi

Lee³

et al. 2021

Anti-Cancer Drugs

View full text Add to dashboard Cite

Reports on the association between the solute carrier organic anion transporter 1B1 (SLCO1B1) T521C polymorphism and methotrexate-induced hepatotoxicity in patients with malignancies are inconsistent. This meta-analysis evaluated the association between the SLCO1B1 T521C polymorphism and methotrexateinduced hepatotoxicity. We performed a systematic review of previous reports from the PubMed, Web of Science, and EMBASE databases, and a meta-analysis was conducted. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated to evaluate the effect of the SLCO1B1 T521C polymorphism on the occurrence of methotrexate-induced hepatotoxicity. In total, data from five studies including 465 patients were analyzed. Patients had received a high-dose methotrexate regimen (1-5 g/m 2 ). The SLCO1B1 variant allele (C allele) carriers had a 1.9-fold higher risk of hepatotoxicity than wild-type homozygote carriers (TT; OR, 1.94; 95% CI, 1. 14-3.31). This meta-analysis demonstrated that C allele carriers of the SLCO1B1 polymorphism had a higher risk of hepatotoxicity than patients with the TT genotype. The SLCO1B1 T521C polymorphism may be a useful predictor for methotrexate-induced hepatotoxicity in patients with malignancies.

show abstract

Section: Discussionmentioning

confidence: 99%